type 1 diabetes and glp 1 GLP-1 for Weight Loss GLP-1 receptor agonists and type

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

However, in MASH with significant fibrosis ( F2), pharmacological therapy provides measurable clinical benefits and should be considered with priority, especially if obesity or T2DM coexist (Fig

Exploring potential synergistic effects of GLP-1RAs with other established therapies, such as SGLT2 inhibitors, could unlock combination approaches for improved outcomes

Diabetes, Obesity and Metabolism, 27(1), 4556

They don't contain actual GLP-1 medications and have no clinical evidence supporting their effectiveness

Observational studies using real-world data have generally corroborated these findings